Prime Medicine (PRME) Earnings Date, Estimates & Call Transcripts $1.32 -0.01 (-0.75%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.30 -0.03 (-1.89%) As of 04/15/2025 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock Prime Medicine Earnings Summary Actual EPS (Mar. 7) -$1.65 Missed By -$1.65 Prime Medicine issued Full Year earnings on March 7, 2025, reporting an EPS of -$1.65. With a trailing EPS of -$1.65, Prime Medicine's earnings are expected to grow next year, from ($1.68) to ($1.35) per share. Full Year Earnings ResourcesFull Year Earnings Report Get Prime Medicine Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prime Medicine and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataPRME Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PRME Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Prime Medicine Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.35-$0.34-$0.35Q2 20252-$0.35-$0.34-$0.35Q3 20252-$0.33-$0.29-$0.31Q4 20252-$0.33-$0.30-$0.32FY 20258($1.36)($1.27)($1.32) Remove Ads Prime Medicine Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails3/7/2025Full Year--$1.65 -$1.65---11/12/2024--$0.43-$0.44 -$0.01-$0.44$55.00M$0.21M8/8/2024--$0.40-$0.46 -$0.06-$0.46--5/10/2024Q1 2024-$0.45-$0.44+$0.01-$0.44-$0.59M3/1/2024Q4 2023-$0.48-$0.56 -$0.08-$0.41--11/3/2023Q3 2023-$0.45-$0.55 -$0.10-$0.55--8/7/2023Q2 2023-$0.42-$0.47 -$0.05-$0.47--5/11/2023Q1 2023-$0.42-$0.44 -$0.02-$0.44-- Prime Medicine Earnings - Frequently Asked Questions When did Prime Medicine announce their last quarterly earnings? Prime Medicine (NYSE:PRME) last announced its quarterly earning data on Friday, March 7, 2025. Learn more on PRME's earnings history. How much revenue does Prime Medicine generate each year? Prime Medicine (NYSE:PRME) has a recorded annual revenue of $2.98 million. How much profit does Prime Medicine generate each year? Prime Medicine (NYSE:PRME) has a recorded net income of -$198.13 million. PRME has generated -$1.65 earnings per share over the last four quarters. What is Prime Medicine's EPS forecast for next year? Prime Medicine's earnings are expected to grow from ($1.68) per share to ($1.35) per share in the next year. More Earnings Resources from MarketBeat Related Companies Xeris Biopharma Earnings Date Intellia Therapeutics Earnings Date Evolus Earnings Date Avadel Pharmaceuticals Earnings Date Cronos Group Earnings Date Praxis Precision Medicines Earnings Date Oculis Earnings Date ChromaDex Earnings Date Nuvation Bio Earnings Date AbCellera Biologics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NYSE:PRME) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRME Stock Free PRME Stock Alerts